Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma.
about
Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular DystrophyCorrelating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.Delivery is key: lessons learnt from developing splice-switching antisense therapiesAntisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo applicationDose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes.Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modifications.A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.Preclinical studies on intestinal administration of antisense oligonucleotides as a model for oral delivery for treatment of duchenne muscular dystrophy.Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse ColitisDevelopment and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides.Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic MiceResults from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophyDownregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake.An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man studyDisposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.Bioanalysis of siRNA and oligonucleotide therapeutics in biological fluids and tissues.Characterisation of aptamers for therapeutic studies.The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice.Studies of DNA Aptamer OliGreen and PicoGreen Fluorescence Interactions in Buffer and SerumPolysome shift assay for direct measurement of miRNA inhibition by anti-miRNA drugs.Lack of QT Prolongation for 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy SubjectsPharmacokinetics and biodistribution of recently-developed siRNA nanomedicinesPreclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model.Long-term Exon Skipping Studies With 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models.Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophyTolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a 'first in man' phase I investigation.Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay.Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses.Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions.Preliminary investigation into the use of a real-time PCR method for the quantification of an oligonucleotide in human plasma and the development of novel acceptance criteria.Dual ligation hybridization assay for the specific determination of oligonucleotide therapeutics.Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice.A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
P2860
Q28831088-53C4EE20-4CE1-44D1-9627-2F39ADD5DA5AQ30837863-B04DCE42-8144-4A8F-A2EB-A3D40E490AE7Q33625875-ABC19FAD-8E30-40B9-B103-C338AE60A4F1Q34168139-23E1F8ED-0900-41C7-8A26-2DF9A3D1DF84Q34293659-12503B9F-9E89-497A-8792-78563357B02DQ34527422-D4C6B51E-000F-4561-B620-18B0DDF025B5Q34656454-CE458210-C2D0-492E-A1F4-ED309530F7C5Q35133925-DA1D71BD-304B-4FD7-A5D5-50FD8240EA95Q35596970-09A540D6-D506-4661-BFE3-2F3B81A76A1CQ35691719-593CB34A-049B-4F88-9162-11B84603CF9FQ35694243-9D36A65E-84C6-4EED-8250-50A01F03AB3EQ36075877-11F23E60-0810-422E-A2B8-53D109B92534Q36078437-F09B0875-5F07-4533-A183-25D00E91DD3BQ36086300-A1676560-8713-4BCB-90C7-FF1561847666Q36661721-483CD19B-F79C-4828-AF1B-06B9AF5C7E9EQ36738386-582AC43B-8760-460B-9FC8-07F4C403BDBBQ36957167-3A455EB7-18F6-4439-BAFE-9F46A0501CF5Q37015657-5B1666CC-156A-42B2-95BC-5E4F660D0AFFQ37238891-6916266D-B2AB-4F2C-BF4B-5EC338A96BEFQ37810190-CA81DB8C-1288-471E-A597-4DC81CF82C91Q38089865-4EFCC273-4A36-42A6-B490-7B5EC54514A5Q38257312-E4BF1B7F-6604-4358-89F4-CBA8ADF37E30Q38292387-9744B189-D169-4497-969F-1359DE053676Q38296452-1E748B3F-641C-40E8-B441-208EC349E4BFQ38629087-C6A46A00-C6FF-4B0F-8731-72A9C824D69DQ38674444-82603169-0F17-43B6-A9C9-1039A1AAA632Q39880997-31E88AA5-68A1-4BDB-99E7-8EB75DD14E19Q42507352-FC0D4D48-719E-4BF6-B39F-81D98BC7E241Q42587467-67CB0A88-6AD2-4064-9148-BC3176C9A181Q42592219-C51053C2-A5B9-409D-B318-92243F20E4BFQ42684786-1DFB8375-962E-4EC1-9D88-9A313022F2D0Q47815341-4F440C18-3118-4525-BEF9-0821BB3B0422Q47941071-61349D59-9DAF-4FFF-B8A1-6301BD325C89Q51599499-34CE2395-A1AA-4660-8948-E549DB538E0DQ54227861-37330889-7836-4D61-8FED-8FE99E15E8D3Q54383995-370A875A-96A0-4DEF-A88A-3769DAE157E1Q54692531-2BBB2426-88FC-47FD-B4F3-E47E060B197CQ58772475-C4BC62CF-5A7E-4723-8822-28D870B9A08C
P2860
Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Development of an ultrasensiti ...... ligodeoxynucleotide in plasma.
@en
type
label
Development of an ultrasensiti ...... ligodeoxynucleotide in plasma.
@en
prefLabel
Development of an ultrasensiti ...... ligodeoxynucleotide in plasma.
@en
P2093
P356
P1476
Development of an ultrasensiti ...... ligodeoxynucleotide in plasma.
@en
P2093
Alfred Chappell
Arthur A Levin
Brenda Baker
Ellen Cheung
Richard S Geary
Rosie Z Yu
P356
10.1006/ABIO.2002.5576
P407
P577
2002-05-01T00:00:00Z